BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 24, 2006
 |  BioCentury  |  Strategy

Two steps to the GP market

Actelion Ltd. says its deal with Roche to develop and commercialize Actelion's oral sphingosine 1-phosphate receptor 1 (S1P1) agonist for autoimmune indications cements its plan to move from marketing niche products to selling general practitioner products.

Under the deal, Actelion (SWX:ATLN, Allschwil, Switzerland) will fund development through Phase II for the first two indications, and the partners will split the costs of subsequent development. They will co-promote products, equally sharing promotion costs and profits worldwide.

ATLN will receive $75 million up front and is eligible for up to $555 million in milestones for the first compounds for all targeted indications. Roche (SWX:ROCZ, Basel, Switzerland) would pay additional milestones for further S1P1 receptor agonists, plus royalties.

Even though a Phase I trial of ACT-S1P1 is ongoing, ROCZ had access to the blinded data, ATLN CEO Jean-Paul Clozel told BioCentury. The effects of ACT-S1P1 were ascertainable from those data, he added.

ATLN had previously said it would disclose results around year end, but with this deal in hand, Clozel said it is unclear when the partners will release the data.

According to Clozel, ATLN did the deal so...

Read the full 940 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >